8-K: BioCardia Regains Nasdaq Compliance with Capital Raises

BioCardia, Inc. announced it believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement after multiple capital raises.

Summary

• BioCardia, Inc. previously received a notification on April 1, 2025, from Nasdaq Listing Qualifications Staff that its stockholders' equity had fallen below the $2,500,000 minimum required for continued listing under Nasdaq Listing Rule 5550(b)(1).
• The company submitted a plan to regain compliance on May 15, 2025, and was granted an extension until September 29, 2025.
• To address the deficiency, BioCardia completed several capital raises, including a private placement on April 23, 2025, yielding $719,000 in net proceeds from 406,818 common shares and warrants.
• A second private placement closed on June 30, 2025, generating $529,000 in net proceeds from 274,696 common shares and warrants.
• On September 19, 2025, the company consummated the sale of 4,800,000 common shares and accompanying warrants, resulting in approximately $5.1 million in net proceeds.
• Additionally, through an At The Market (ATM) offering agreement with H.C. Wainwright & Co., LLC, from April 1, 2025, to September 24, 2025, BioCardia sold 446,215 common shares at an average price of $2.55, generating $1.0 million in net proceeds.
• As a result of these transactions, the company believes its stockholders' equity now exceeds $2.5 million, thereby regaining compliance with Nasdaq's requirement.

Sentiment

Score: 7

Explanation: Successfully addressed a critical Nasdaq listing compliance issue by raising substantial capital, which is a significant positive. However, the need for these raises stemmed from a prior failure to meet minimum equity requirements, indicating past financial challenges.

Positives

• Successfully raised over $7.3 million through multiple capital raises, significantly improving the company's financial position.
• Regained compliance with Nasdaq's minimum $2.5 million stockholders' equity requirement, mitigating immediate delisting risk.
• Secured an extension from Nasdaq until September 29, 2025, providing time to execute the compliance plan.

Negatives

• Previously failed to meet Nasdaq's minimum stockholders' equity requirement, indicating past financial challenges.
• The capital raises involved the issuance of new shares and warrants, leading to shareholder dilution.

Risks

• Nasdaq will continue to monitor ongoing compliance with the stockholders' equity requirement.
• If the company does not evidence compliance at the time of its next periodic report, it may again be subject to delisting.
• Reliance on future capital raises or operational profitability to maintain compliance with listing standards.

Future Outlook

The company expects to maintain compliance with Nasdaq listing standards, but Nasdaq will continue to monitor its ongoing compliance with the stockholders' equity requirement. Failure to evidence compliance in the next periodic report could lead to delisting.

Management Comments

• Believes it has regained compliance with the minimum $2.5 million stockholders equity requirement for continued listing.
• Stockholders equity exceeds $2.5 million as of the date of this Report.

Industry Context

Biotechnology and medical device companies frequently rely on capital raises to fund research, development, and operational expenses. Maintaining a listing on a major exchange like Nasdaq is critical for these companies to access capital markets, enhance liquidity for investors, and maintain corporate visibility and credibility within the industry.

Related Party Transactions

• Certain members of the board of directors and executive officers participated in the private placements on April 23, 2025, and June 30, 2025.

Stakeholder Impact

• Shareholders: Reduced immediate delisting risk, but experienced dilution from the issuance of new shares and warrants.
• Investors: Increased confidence due to regained Nasdaq compliance, but ongoing monitoring by Nasdaq introduces future uncertainty regarding sustained compliance.

Next Steps

• Nasdaq will continue to monitor the company's ongoing compliance with the stockholders' equity requirement.
• The company must evidence compliance in its next periodic report to avoid potential delisting.

Key Dates

Recommendation

The company successfully addressed its immediate Nasdaq listing compliance issue by raising significant capital, which removes an overhang and is a positive development. However, the need for these capital raises highlights underlying financial challenges. While the immediate delisting risk is mitigated, Nasdaq's continued monitoring and the company's ability to sustain compliance in the long term remain factors. The dilution from recent offerings also needs to be considered. A 'Hold' recommendation is appropriate as the company has resolved a critical issue, but further sustained financial performance is needed to warrant a more bullish stance.

Keywords

BioCardia, BCDA, Nasdaq, Listing Compliance, Stockholders Equity, Capital Raise, Private Placement, ATM Offering, Warrants, Delisting Risk